$1 billion-plus drugs seen reaching market in 2016
Send a link to a friend
[February 03, 2016]
LONDON (Reuters) - Drug companies
are likely to launch seven "blockbuster" drugs in 2016, each with $1
billion-plus annual sales potential, led by new treatments for liver
disease and HIV, according to a Thomson Reuters analysis.
The assessment means the pharmaceuticals industry is on track for
another productive year, although not as good as 2015, which saw the
arrival of 11 new blockbusters.
The two top hits of 2016 are tipped to be Intercept Pharmaceuticals'
<ICPT.O> chronic liver disease drug obeticholic acid, with a
consensus sales forecast of $2.6 billion in 2020, and Gilead
Sciences' <GILD.O> new fixed dose HIV drug emtricitabine plus
tenofovir alafenamide, on $2.0 billion.
Other products expected to launch this year with forecast sales
above $1 billion in 2020 include a new hepatitis C drug from Merck <MRK.N>
and a leukemia medicine from AbbVie <ABBV.N>, according to the
annual "Drugs to Watch" report.
Two keenly awaited Roche <ROG.VX> drugs, each with forecast sales of
around $3 billion, are not on list because it is unclear if
atezolizumab for cancer and ocrelizumab for multiple sclerosis will
be commercially available this year or next.
(Reporting by Ben Hirschler Editing by Jeremy Gaunt)
[© 2016 Thomson Reuters. All rights
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.